Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

(2020) Kenneth V.I. Rolston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus

(2019) Rebekah M. Dedrick et al.   NATURE MEDICINE

Early clinical experience of bacteriophage therapy in 3 lung transplant recipients

(2019) Saima Aslam et al.   AMERICAN JOURNAL OF TRANSPLANTATION

In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models

(2019) Rio Nakamura et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy

(2019) Anca M Segall et al.   CURRENT OPINION IN MICROBIOLOGY

Phage therapy against Achromobacter xylosoxidan s lung infection in a patient with cystic fibrosis: a case report

(2018) N. Hoyle et al.   RESEARCH IN MICROBIOLOGY

Cefiderocol for treatment of complicated urinary tract infections

(2018) Florian M E Wagenlehner et al.   LANCET INFECTIOUS DISEASES

Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa

(2016) Benjamin K. Chan et al.   Scientific Reports

Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients

(2009) C.R. Hansen et al.   Journal of Cystic Fibrosis